Reprimo methylation is a potential biomarkerof Barrett's-associated esophageal neoplastic progression

Clinical Cancer Research

Volumn 12, Issue 22, 2006, Pages 6637-6642

  Hamilton, James P ^a   Sato, Fumiaki ^a   Jin, Zhe ^a   Greenwald, Bruce D ^b   Ito, Tetsuo ^a   Mori, Yuriko ^a   Paun, Bogdan C ^a   Kan, Takatsugu ^a   Cheng, Yulan ^a   Wang, Suna ^b   Yang, Jian ^a   Abraham, John M ^a   Meltzer, Stephen J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BIOLOGICAL MARKER; PROTEIN P53;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CARCINOGENESIS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DRUG MECHANISM; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; PRIORITY JOURNAL; REPRIMO GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS EPITHELIUM; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; AZACITIDINE; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; ESOPHAGEAL DISEASES; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC MARKERS; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS;

EID: 33845337967     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1781     Document Type: Article

References (50)

1. 2 phase. J Biol Chem 2000;275:22627-30.
2. Otsuka T, Kohno T, Mori M, Noguchi M, Hirohashi S, Yokota J. Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chromosomes Cancer 1996;16:113-9.
3. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157-62.
4. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21.
5. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
6. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
7. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
8. Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003;95:1747-57.
9. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
10. Wong TS, Kwong DL, Sham JS, Wei WI, Yuen AP. Methylation status of Reprimo in head and neck carcinomas. Int J Cancer 2005;117:697.
11. Suzuki M, Shigematsu H, Takahashi T, et al. Aberrant methylation of Reprimo in lung cancer. Lung Cancer 2005;47:309-14.
12. Takahashi T, Suzuki M, Shigematsu H, et al. Aberrant methylation of Reprimo in human malignancies. Int J Cancer 2005;115:503-10.
13. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
14. Pera M, Manterola C, Vidal O, Grande L. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 2005;92:151-9.
15. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
16. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2005;128:1554-66.
17. Schulmann K, Sterian A, Berki A, et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005;24:4138-48.
18. Feagins LA, Souza RF. Molecular targets for treatment of Barrett's esophagus. Dis Esophagus 2005;18:75-86.
19. Hamilton JP, Sato F, Greenwald BD, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006;4:701-8.
20. Meltzer SJ, Yin J, Manin B, et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 1994;54:3379-82.
21. Sato F, Shibata D, Harpaz N, et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res 2002;62:6820-2.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
23. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
24. Shibata DM, Sato F, Mori Y, et al. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. Cancer Res 2002;62:5637-40.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
26. Sharma P, Morales TG, Sampliner RE. Short segment Barren's esophagus - the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol 1998;93:1033-6.
27. Zhang Z, Li J, Lantry LE, et al. p53 transgenic mice are highly susceptible to 1,2-dimethylhydrazine-induced uterine sarcomas. Cancer Res 2002;62:3024-9.
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
29. Levine AJ, Finlay CA, Hinds PW. P53 is a tumor suppressor gene. Cell 2004;116:867-9,1 p following S9.
30. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996;1287:77-102.
31. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
32. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
33. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-57.
34. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53-regulated genes. Proc Natl Acad Sci USA 1999;96:14517-22.
35. 2-M transition by p53. Oncogene 2001;20:1803-15.
36. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
37. Bennett WP, Hollstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092-7.
38. Cameron AJ. Management of Barrett's esophagus. Mayo Clin Proc 1998;73:457-61.
39. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
40. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
41. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32:379-88.
42. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000;95:1888-93.
43. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol 2004;39:1175-9.
44. Wang S, Zhan M, Yin J, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006;25:3346-56.
45. Momparler RL. Epigenetic therapy of cancer with 5-aza-2′- deoxycytidine (decitabine). Semin Oncol 2005;32:443-51.
46. Lemaire M, Momparler LF, Bernstein ML, Marquez VE, Momparler RL. Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs 2005;16:301-8.
47. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 1998;58:5489-94.
48. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-40.
49. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-6.
50. Rashid A, Issa JP. CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology 2004;127:1578-88.